Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 15/20 | 0.60 |
| ▸ | CNR1 | P21554 | 3/20 | 0.54 |
| ▸ | CDC25A | P30304 | 1/20 | 0.53 |
| ▸ | ICMT | O60725 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29388385 | 1.00 | CNR2 (0.60) | CNR2CNR1CDC25AICMT | |
| SCHEMBL29385124 | 0.84 | CNR2 (0.58) | CNR2CNR1CDC25AICMT | |
| SCHEMBL19638822 | 0.84 | CNR2 (0.58) | CNR2CNR1CDC25AICMT | |
| SCHEMBL29387877 | 0.80 | CNR1 (0.64) | CNR2CNR1 | |
| SCHEMBL19638909 | 0.80 | CNR1 (0.64) | CNR2CNR1 | |
| SCHEMBL17464416 | 0.80 | CNR2 (0.61) | CNR2CNR1CDC25AICMT | |
| SCHEMBL29387653 | 0.80 | CNR2 (0.61) | CNR2CNR1CDC25AICMT | |
| SCHEMBL13131369 | 0.77 | CDC25A (0.72) | CNR2CNR1CDC25AICMT | |
| SCHEMBL29410253 | 0.76 | CNR2 (0.60) | CNR2CNR1 | |
| SCHEMBL19638929 | 0.76 | CNR2 (0.60) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4322931-A1 | TRANSDERMAL DELIVERY OF CANNABIDIOL | Pike Therapeutics Inc. (CA) | 2024-02-21 | — | — | EP | disclosed |
| WO-2024018420-A1 | CONTINUOUS DELIVERY SYSTEMS COMPRISING A CANNABINOID AND MEDICINAL USES THEREOF | Pike Therapeutics Inc. (CA) | 2024-01-25 | — | — | WO | disclosed |
| EP-4196113-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING PARKINSON'S DISEASE | Pike Therapeutics, Inc. (CA) | 2023-06-21 | — | — | EP | disclosed |
| EP-4175629-A1 | TRANSDERMAL PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF MULTIPLE SCLEROSIS | Pike Therapeutics, Inc. (CA) | 2023-05-10 | — | — | EP | disclosed |
| WO-2023012691-A1 | TRANSDERMAL MICRO-DOSING DELIVERY OF PHARMACEUTICAL AGENTS | PIKE THERAPEUTICS, INC. (CA) | 2023-02-09 | — | — | WO | disclosed |
| WO-2022038475-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING PARKINSON'S DISEASE | PIKE THERAPEUTICS, INC. (CA) | 2022-02-24 | — | — | WO | disclosed |
| WO-2022003623-A1 | TRANSDERMAL PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF MULTIPLE SCLEROSIS | PIKE THERAPEUTICS, INC. (CA) | 2022-01-06 | — | — | WO | disclosed |
| EP-3247402-A1 | COMPOSITION AND METHODS TO IMPROVE STABILITY, DOSING, PHARMACODYNAMICS AND PRODUCT SHELF LIFE OF ENDOCANNABINOIDS, PHYTOCANNABINOIDS AND SYNTHETIC CANNABINOIDS DELIVERED BY NASAL INHALER | Willinsky, Michael (CA) | 2017-11-29 | — | — | EP | disclosed |